Chemicals · NSE: PRIVISCL
Privi Speciality Chemicals
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 30 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹13,140Cr
- P/E
- 35.2×
- 1Y return
- +3.69%
- From 52W high
- −11.1%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 760 | 679 | +12.0% | 666 | +14.1% |
| EBITDA | 200 | 182 | +9.8% | 152 | +31.2% |
| EBITDA margin | 26.3% | 26.8% | -55 bps | 22.9% | +341 bps |
| PBTProfit before tax | 159 | 125 | +26.8% | 113 | +39.9% |
| Net profit | 117 | 90 | +29.7% | 84 | +39.0% |
| EPS (₹) | 29.96 | 24.04 | +24.6% | 21.56 | +39.0% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY26 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.
Guidance
Management confident of reaching its 5K:1K plus vision by 2030
Narayan S. Iyer · Chief Financial Officer · p. 5
Management confident of reaching its 5K:1K plus vision by 2030
“We expect to maintain the momentum of growth in the near future and are working towards achieving our vision set about of the 5K:1K plus and are very confident of achieving the same by 2030.”
EBITDA margin guided to stay at current level
Sanjeev Patil · Executive Vice President · Q&A · p. 9
EBITDA margin guided to stay at current level
“And also, we will be able to maintain the EBITDA margin where we are right now. So that is the guidance on the EBITDA.”
More figures from the call
“Our Phase 1 program is designed to increase install capacity from 48,000 metric tons per annum to 54,000 metric tons per annum, representing an addition of 6,000 metric tons per annum. As of 30th September 2026, this project has been completed.”
“And capacity utilization is as much as 85%. We are not able to expand the capacity. Everything is ready, but there are some permissions which we are waiting for.”
“So, we have about 6,000 tons of capacity, which is there, which can possibly give us a potential revenue of about INR300 crores, INR350 crores, which we've been talking about basis the prices that is there.”
“And Phase 3, as we are talking about, where we indicated a broad capex of about INR400-odd crores, INR400 crores to INR425 crores, that will give an additional revenue of close to another INR450 crores to INR500 crores, broadly about that.”
“So this INR1,000 crores plus that INR500 crores of the specialty and the Phase 1, which has the potential of generating about INR450 crores.”
In short
- 01Management kept its 20% growth guidance for FY27 and for the coming years.
- 02For FY28, management expects at least 20% growth, revenue near Rs 3,750-4,000 crore, and steady EBITDA margin.
- 03Q2 FY27 total income was Rs 773.16 crore (up 13.9%) and PAT Rs 117.03 crore (up 24.61%).
- 04Phase 1 capacity rise from 48,000 to 54,000 MTPA is complete; volumes expected mainly in Q4.
- 05Phase 2 (maltol, ethyl maltol and others) due June-September next year, with revenue from October 2027.
- 06About Rs 1,000 crore of capex remains for Phases 2 and 3; company targets Rs 5,000 crore revenue by 2030.
- 07First ever interim dividend of Rs 5 per share declared.
- 08Privi Fine Sciences is waiting for regulatory approvals before it can expand capacity.
Capex
Maltol, ethyl maltol, ethyl vanillate and cyclopentanone planned in later expansion phases
Sanjeev Patil · Executive Vice President · p. 4
Maltol, ethyl maltol, ethyl vanillate and cyclopentanone planned in later expansion phases
“We are on course for implementing maltol, ethyl maltol, ethyl vanillate, that is Musty, and cyclopentanone along with other molecules planned as part of subsequent phases of expansion.”
Phase 2 to finish by June, commercial sales from second half of next year
Sanjeev Patil · Executive Vice President · Q&A · p. 7
Phase 2 to finish by June, commercial sales from second half of next year
“Phase 2 will happen, and it will be effectively available for commercial sales from second half of next financial year. So we are planning to complete everything by June and from September onwards because there will be trial production and all of that.”
Next expansion covers furfural-based derivatives, maltol, ethyl maltol and cyclopentanone
Sanjeev Patil · Executive Vice President · Q&A · p. 8
Next expansion covers furfural-based derivatives, maltol, ethyl maltol and cyclopentanone
“That's furfural-based derivatives, maltol, ethyl maltol, cyclopentanone, and a couple of specialty molecules as well.”
New products made on pilot basis and sold to customers during the 1-year build
Sanjeev Patil · Executive Vice President · Q&A · p. 14
New products made on pilot basis and sold to customers during the 1-year build
“So, what the way we do it is during this 1 year that we will be putting up this project, we would be manufacturing these products on pilot basis and selling it to our customers so that in terms of quality, in terms of various other issues, those are all sorted out by the time the commercial production starts.”
Capital to go to capacity expansion, new specialty products and operational improvements
Narayan S. Iyer · Chief Financial Officer · p. 5
Capital to go to capacity expansion, new specialty products and operational improvements
“Looking ahead, we will continue to allocate capital towards capacity expansion, new specialty products and operational improvements while maintaining a strong focus on profitable growth and cash generation.”
Capacity
Overall plant utilisation around 85-90%
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 7
Overall plant utilisation around 85-90%
“As informed, the overall utilization of all our plants has been around the 85%, 90%. So we expect to maintain the momentum of growth in all.”
Segments
Privi Fine Sciences: Privi Fine Sciences numbers expected to improve next financial year
Sanjeev Patil · Executive Vice President · Q&A · p. 12
Privi Fine Sciences: Privi Fine Sciences numbers expected to improve next financial year
“We have not been able to expand the capacity because of those regulatory approvals that I'm talking about, so which would be in place during the next few months. And then next financial year, you will definitely see numbers which are closer to what you said.”
Privi Fine Sciences: Privi Fine Sciences to break even only once permissions allow full capacity
Sanjeev Patil · Executive Vice President · Q&A · p. 13
Privi Fine Sciences: Privi Fine Sciences to break even only once permissions allow full capacity
“The full capacity is not yet realized. That will be realized only when we get those permissions, and that's when it will break even and be in that.”
PRIGIV JV: JV revenue could go beyond Rs 225 crore once third phase is in place
Sanjeev Patil · Executive Vice President · Q&A · p. 14
PRIGIV JV: JV revenue could go beyond Rs 225 crore once third phase is in place
“So once that is in place, then we can go beyond INR225 crores also. But surely, we are confident.”
Demand
Significant volume growth expected in Q4 as new contracts start
Sanjeev Patil · Executive Vice President · Q&A · p. 6
Significant volume growth expected in Q4 as new contracts start
“Now I am saying that the volumes will come in quarter 4 when we get the new contracts. So in quarter 4, you will find significant volume growth.”
Aroma chemical usage rising; more pinene use and Africa market growing
Mahesh Babani · Chairman and Managing Director · Q&A · p. 7
Aroma chemical usage rising; more pinene use and Africa market growing
“See, our market's usage of aroma chemicals is increasing significantly. Lots of new things are coming, new people are using more and more pinene. Africa market is growing.”
Customers have indicated they will buy more
Mahesh Babani · Chairman and Managing Director · Q&A · p. 9
Customers have indicated they will buy more
“And we have got first cuts from the customers that they are going to buy more, and we are happy to say that our guidance is a positive outlook.”
European crises seen creating opportunities for compliant Indian makers
Sanjeev Patil · Executive Vice President · Q&A · p. 9
European crises seen creating opportunities for compliant Indian makers
“And in terms of our future outlook, we see great opportunities coming forward because all those things that you mentioned, create a huge amount of opportunities for manufacturers in India who are compliant, who are quality conscious and who follow all the sustainability norms.”
Very positive outlook for market and customers on next year's contracts
Sanjeev Patil · Executive Vice President · Q&A · p. 14
Very positive outlook for market and customers on next year's contracts
“But situation is extremely good. All is well and better. So, we are seeing very positive outlook for the market and for our customers.”
Margins and costs
Expenses came down to 9.72% of sales
Narayan S. Iyer · Chief Financial Officer · p. 5
Expenses came down to 9.72% of sales
“All our expenses during the year have been under control and in fact, have come down. And if we compare as a percentage of sales, it works to 9.72%.”
Raw material cost about 52% of sales vs 54% in Q1 and 51% a year ago
Narayan S. Iyer · Chief Financial Officer · p. 5
Raw material cost about 52% of sales vs 54% in Q1 and 51% a year ago
“Apart from this, the RMC as a percentage of sales has come down to about 52% as compared to 54% in quarter 1 and as against 51% for September '25 of the previous year.”
Q2 EBITDA margin 27.48% vs 26.12%
Narayan S. Iyer · Chief Financial Officer · p. 5
Q2 EBITDA margin 27.48% vs 26.12%
“EBITDA margins remained a healthy 27.48% in quarter 2 of financial year '27 as against 26.12% for the financial year '26-'27.”
Higher sales base spread fixed costs and improved EBITDA margins
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 8
Higher sales base spread fixed costs and improved EBITDA margins
“However, we were able to ensure to maintain and improve the EBITDA margins on the other expenses because with the higher base that we have been able to do, we have been able to amortize the fixed expenses, and that's how the EBITDA margins have improved, in fact.”
EBITDA-to-PAT conversion improving over 4-5 quarters as interest cost falls
Sanjeev Patil · Executive Vice President · Q&A · p. 8
EBITDA-to-PAT conversion improving over 4-5 quarters as interest cost falls
“And also conversion of EBITDA into PAT also has been improving if you see for the last 4 or 5 quarters, which reflects that we use assets much better and also the interest cost is coming down.”
Debt and working capital
ROCE 24.30%, up 216 bps; ROE 26.34%, up 134 bps
Narayan S. Iyer · Chief Financial Officer · p. 5
ROCE 24.30%, up 216 bps; ROE 26.34%, up 134 bps
“As on 30th September 2026, our ROCE stood at 24.30%, an improvement of 216 basis points year-on-year, while ROE increased by 134 basis points, and we have achieved a figure of 26.34%.”
Net debt to EBITDA 1.07x; net debt to equity 0.51x
Narayan S. Iyer · Chief Financial Officer · p. 5
Net debt to EBITDA 1.07x; net debt to equity 0.51x
“Our net debt-to-EBITDA ratio stood at 1.07x, and our net debt to equity was 0.51x.”
Net debt Rs 814.51 crore; working capital cycle below 100 days from 124
Narayan S. Iyer · Chief Financial Officer · p. 5
Net debt Rs 814.51 crore; working capital cycle below 100 days from 124
“In absolute terms, our net debt as on 30th September 2026 was INR814.51 crores. Our working capital cycle has also come down to less than 100 days during this quarter from the 124 days, which we achieved in the same period in the previous year.”
Cash from operations Rs 445 crore in H1
Narayan S. Iyer · Chief Financial Officer · p. 5
Cash from operations Rs 445 crore in H1
“Our cash generated from operations for the first 6 months was INR445 crores, showing remarkable improvement over previous year, mainly on account of higher profits earned during this year.”
Long-term working capital cycle expected at about 105-110 days
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 11
Long-term working capital cycle expected at about 105-110 days
“You should, on a long term, on an annual basis, expect a working capital cycle in the range of about 105 to 110 days broadly.”
Acquisitions and new business
PRIGIV: PRIGIV joint venture made a profit in Q2 FY27 after first profit in Q4 FY26
Sanjeev Patil · Executive Vice President · p. 4
PRIGIV: PRIGIV joint venture made a profit in Q2 FY27 after first profit in Q4 FY26
“The joint venture had achieved its first profitable quarter in Q4 FY26, and indeed in Q2 FY27, PRIGIV has made profit.”
New partnership agreements still work in progress
Sanjeev Patil · Executive Vice President · Q&A · p. 6
New partnership agreements still work in progress
“So we are working on those. It takes time, as you know, and it is work in progress. And in due course of time, we will inform you about those.”
PRIGIV: PRIGIV JV Q2 sales about Rs 28 crore with PBT near Rs 2 crore; H1 sales Rs 47 crore
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 11
PRIGIV: PRIGIV JV Q2 sales about Rs 28 crore with PBT near Rs 2 crore; H1 sales Rs 47 crore
“So as indicated by Mr. Sanjeev, in this quarter, we have achieved a sales of about INR28 crores with a positive PBT of about close to INR2 crores or so. And overall, for first 6 months, we have achieved a sales of about INR47 crores and a negligible loss of INR0.02 lakhs or so, in fact.”
Privi Fine Sciences: Privi Fine Sciences: 4 of 5 products already supplied to top multinationals
Sanjeev Patil · Executive Vice President · Q&A · p. 12
Privi Fine Sciences: Privi Fine Sciences: 4 of 5 products already supplied to top multinationals
“But what is important is that we have 5 different products, out of which 4 products are already being supplied to the top multinationals.”
Privi Fine Sciences: Merger expected before FY end; unit revenue could rise to Rs 250-300 crore
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 12
Privi Fine Sciences: Merger expected before FY end; unit revenue could rise to Rs 250-300 crore
“And by the time the entire merger process happens, which we expect that it should happen before this financial year ending, we will be in a position to really go all out on manufacturing and achieve the so-called 80%, 85% of the capacities so that our revenue from so-called INR100-odd crores, what we could achieve can go to the INR250crores, INR300 crores mark, in fact.”
Dividends and buybacks
First ever interim dividend of Rs 5 per share declared for FY27
Mahesh Babani · Chairman and Managing Director · p. 3
First ever interim dividend of Rs 5 per share declared for FY27
“the Board has declared the company's first ever interim dividend of INR5 per share of face value INR10 for the financial year '26-'27.”
One-offs
State incentives Rs 1.62 crore so far this year vs Rs 9 crore last year; more expected
Narayan S. Iyer · Chief Financial Officer · p. 5
State incentives Rs 1.62 crore so far this year vs Rs 9 crore last year; more expected
“In the previous year, out of the total revenue that we earned, an amount of INR9 crores was on account of state incentives received. And during the current year, an amount of INR1.62 crores has been received. We expect to receive more going forward during the financial year.”
Incentives in next 6 months expected to exceed last year's amount
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 8
Incentives in next 6 months expected to exceed last year's amount
“We expect to receive more incentive going forward in the next 6 months or so, in fact. So the amount will be, I think, higher than what we have earned in the previous year.”
Balance incentive due in next 2 quarters about Rs 12-15 crore
Sanjeev Patil · Executive Vice President · Q&A · p. 8
Balance incentive due in next 2 quarters about Rs 12-15 crore
“The amount should be in the range of about INR12 crores to INR15 crores.”
Last year's Q2 EBITDA margin helped by Rs 9 crore state incentive
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 10
Last year's Q2 EBITDA margin helped by Rs 9 crore state incentive
“Last year, said Q2, we were able to get that INR9 crores of state incentives. So that's why that a little bit of EBITDA margins also improved on account of that.”
Risks
About 70% of revenue from non-petroleum raw materials; little impact from West Asia war
Sanjeev Patil · Executive Vice President · Q&A · p. 7
About 70% of revenue from non-petroleum raw materials; little impact from West Asia war
“As we always maintain that 2/3 of our revenue, almost 70% of our revenue comes from non- petroleum source raw materials. So we do not have significant impact of this war and the situation like that.”
No raw material procurement challenges from shipping disruption
Sanjeev Patil · Executive Vice President · Q&A · p. 9
No raw material procurement challenges from shipping disruption
“So, answering the second question first, we are not seeing any challenges there in terms of procurement of our raw materials, okay?”
Freight disruption smaller for Privi than for others
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 10
Freight disruption smaller for Privi than for others
“Having said that and also reiterating that freight for us, the disturbance has not been to that extent what others are facing currently, in fact.”
Privi Fine Sciences: Privi Fine Sciences delayed by regulatory approvals, now nearing completion
Sanjeev Patil · Executive Vice President · Q&A · p. 12
Privi Fine Sciences: Privi Fine Sciences delayed by regulatory approvals, now nearing completion
“So, it is waiting for some regulatory approvals. Otherwise, in terms of products, we are good, okay? But in terms of some regulatory approvals, we faced some delays, which are now nearing completion.”
Privi Fine Sciences: Pollution Control Board permissions for expansion expected any time
Sanjeev Patil · Executive Vice President · Q&A · p. 12
Privi Fine Sciences: Pollution Control Board permissions for expansion expected any time
“But then you require permissions for expanding capacity also from the Pollution Control Board and others, which are expected any time now.”
Other
Highest ever quarterly revenue of Rs 773 crore and EBITDA of Rs 212 crore
Sanjeev Patil · Executive Vice President · p. 3
Highest ever quarterly revenue of Rs 773 crore and EBITDA of Rs 212 crore
“As Mahesh bhai mentioned, we have achieved our highest ever quarterly total revenue of INR773 crores and EBITDA of INR212 crores.”
Q2 total income Rs 773.16 crore, up 13.9%; EBITDA up 16.66%; PAT up 24.61%
Narayan S. Iyer · Chief Financial Officer · p. 4
Q2 total income Rs 773.16 crore, up 13.9%; EBITDA up 16.66%; PAT up 24.61%
“Quarter 2 in financial year '26-'27 extended our strong operating momentum with a total income of INR773.16 crores, up 13.9% year-on-year and EBITDA achieved was INR212.49 crores, up 16.66% and a profit after tax of INR117.03 crores, reflecting a 24.61% growth over the previous year.”
Q2 PAT Rs 117 crore, up about 25%; H1 PAT Rs 201 crore, up about 29%
Narayan S. Iyer · Chief Financial Officer · p. 5
Q2 PAT Rs 117 crore, up about 25%; H1 PAT Rs 201 crore, up about 29%
“Profit after tax achieved during the quarter 2 was INR117 crores, which is up by about 25% year-on-year, while PAT for the first half year of '26-'27 was INR201 crores, up by about 29% compared to the previous year.”
Fixed asset turnover at 1.7x; better turnover expected from Phases II and III
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 6
Fixed asset turnover at 1.7x; better turnover expected from Phases II and III
“And as informed going forward, with the new molecules coming in and the high speciality chemicals also setting up, we expect a better asset turnover going forward in the Phase II and Phase III also. But as we speak, our asset turnover is at 1.7x on the fixed asset base, in fact.”
Other income mostly foreign exchange gains
Narayan S. Iyer · Chief Financial Officer · Q&A · p. 10
Other income mostly foreign exchange gains
“So, the other income, prima facie, consists a major part on account of foreign exchange gains, in fact.”
Sources
- Earnings call transcript, Q2 FY27 Filed 3 Nov 2026 · 15 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

